According to Ubist, a drug market research institute, potagel suspension amounted to a total of about 1 billion won in the fourth quarter of last year, accounting for 47% of the market share. The prescription amount increased by 50% compared to the previous quarter, the third quarter, and the market share has doubled.
|
In particular, the market share increased from 36% in October to 49% in November, and reached 56% in December. In January of this year, the potagel suspension accounted for 59% of the market share with a prescription amount of 450 million won.
Potagel suspension containing dioctahedral smectide as the main component is an antidiarrheal agent used to relieve acute/chronic diarrhea and pain in the esophagus, stomach, and duodenum. It acts on the damaged mucous membrane from the esophagus to the intestine and quickly relieves symptoms. Prevents the destruction of mucus-producing cells in the small intestine, and protects the intestine by increasing the amount and quality of mucus. In addition, it removes the cause of diarrhea by adsorbing and excreting pathogenic bacteria, toxins, viruses, gas produced by abnormal fermentation in the intestine, and bile acids.
Smectite, the main component of potagel suspension, is a natural inorganic substance that is not absorbed by the human body. In the event of diarrhea accompanied by abdominal pain, it can be safely taken from infants to adults regardless of age. Recently, the product has been renewed in the form of a stick-type pouch that can be easily squeezed.
An official of Daewon Pharmaceutical said, “It is a product directly produced by Daewon Pharmaceutical’s new cGMP-level factory with excellent facilities, unlike other products sold by importing finished products.” We plan to expand investment in machine R&D.